Resources
Resource
Harmonized Lab Data Analysis Helps Pharma Company Fight Rare Disease
See how timelier data-driven insights enabled faster identification and targeting of potential rare disease patients and treating HCPs.
Resource
New industry evidence demands RWD disruption in pharma
Reuters Events, in partnership with Prognos Health, surveyed 215 brand, marketing, commercial strategy, medical affairs, and data science professionals in the pharmaceutical industry to understand current challenges and opportunities with real-world data (RWD) for therapy commercialization.
Resource
5 Step Guide to Better Underwriting Risk Prediction
Leverage the clinical and diagnostic value of lab data to predict the future cost of healthcare more accurately than manual rate and prescription claims data alone with the PrognosⓇ Underwriting Risk Prediction tool.
Resource
How small and midsize pharma gain economies of scale with an end-to-end RWD Solution
It’s no secret that small and midsize pharma companies don’t have access to the same amount of resources as big pharma. However, you can level the playing field by...
Resource
A Straighter Path to Underwriting
A straighter path to underwriting requires data to accurately predict risk, the visibility to identify high-cost prospects, and insights on the populations you want to insure.
Resource
Prognos Factor Explained
Analyzing de-identified patient data is essential to optimize commercial brand strategy. But current methods of obtaining this data can be challenging. See how you can accelerate your path to clinical truth with interoperable patient data and analytics software.
